# US 2021/0079003 A1 · MTA-Cooperative PRMT5 Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079003 A1
- Document ID: US20210079003A1
- Status: Published application
- Kind: A1
- Application number: 17/018,738
- Filed: 2020-09-11
- Published: 2021-03-18
- Earliest claimed: 2019-09-12
- Assignees: Mirati Therapeutics, Inc.
- Applicants: Mirati Therapeutics, Inc.
- Inventors: Thomas P. Bobinski; Christopher Ronald Smith; Matthew Arnold Marx; John Michael Ketcham; Aaron Craig Burns; John David Lawson; Svitlana Kulyk; Jon Kuehler; Anthony Ivetac
- Web page: https://patentgrep.com/patent/US20210079003A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07D 237/32: with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/14: containing three or more hetero rings
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 403/14: containing three or more hetero rings
- C07D 405/10: linked by a carbon chain containing aromatic rings
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/10: linked by a carbon chain containing aromatic rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/14: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- C12N 9/1007: {Methyltransferases (general) (2.1.1.)}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof:
wherein:
R1 is hydrogen, halogen, hydroxyalkyl, -L-CN, —Y-C1-C5 alkyl, —Y-cycloalkyl, —Y-heterocyclyl, —Y-aryl, —Y-arC1-C3alkyl or —Y-heteroaryl, wherein the cycloalkyl, the heterocyclyl, the aryl, and the heteroaryl portions are each optionally substituted with one or more R2;
each Y is independently a bond or —NR4—;
each R2 is independently hydroxy, halogen, cyano, cyanomethyl, —(NR4)2, hydroxyalkyl, alkoxy, —SO2C1-C3alkyl, —X-arC1-C3alkyl, heteroalkyl, C2-C4 alkynyl, —X-haloalkyl, —X-C1-C5 alkyl, —Z-C1-C5 alkyl, heterocyclyl, —X-L-cycloalkyl, —Z-cycloalkyl, —X-aryl, —Z-aryl, or —X-heteroaryl, wherein the heterocyclyl, the cycloalkyl, the aryl and the heteroaryl are optionally substituted with one or more R5, or;
each X is independently a bond, O, S, —NR4— or —NR4C(O)—;
each Z is independently a bond, —SO—, —SO2—, —CH(OH)— or —C(O)—;
each L is independently a bond or C1-C3 alkylene;
R3a and R3b are each independently hydrogen or deuterium, or R3a and R3b together are oxo;
each R4 is independently hydrogen or C1-C3 alkyl;
each R5 is independently cyano, oxo, halogen, C1-C3 alkyl, hydroxyalkyl, alkoxy, —X-haloalkyl, —Z-cycloalkyl, —X-arC1-C3 alkyl, X-arC1-C3 alkyl substituted with cyano, —X-L-cycloalkyl, —X-L-heteroaryl optionally substituted with one or more C1-C3alkyl or oxo, or —X-aryl; and
R6 is hydrogen, halogen, C1-C3 alkyl, haloalkyl or alkoxy.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein R1 is -Y-heterocyclyl.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein R1 is -Y-aryl, wherein the aryl is optionally substituted with one or more R2.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein R1 is —Y-cycloalkyl.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein R1 is —Y-heteroaryl optionally substituted with one or more R2.

### Claim 6 (depends on 5)

The compound according to claim 5, wherein Y is a bond and the heteroaryl is pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, triazolyl, oxidazolyl, pyridyl, pyridiazinyl, pyrimidinyl, quinolinyl, isoquinolinyl, phthalazinyl, pyrazolopyridinyl, 1H-pyrrolopyridyl, pyrazolopyrimidinyl, imidazopyridyl, tetrahydropyrazolopyrazinyl, 2H-4λ4-imidazopyrimidinyl, 2H-4λ4-imidazopyridazinyl, oxazolopyridyl or 5,6-dihydro-8H-imidazooxazinyl, each optionally substituted with one or more R2.

### Claim 7 (depends on 6)

The compound according to claim 6, wherein the heteroaryl is tetrahydropyrazolopyrazinyl, optionally substituted with one or more R2.

### Claim 8 (depends on 5)

The compound according to claim 5, wherein the heteroaryl is pyridyl, optionally substituted with one or two R2.

### Claim 9 (depends on 8)

The compound according to claim 8, wherein the pyridyl is substituted with one R2, and R2 is hydroxy, halogen, cyano, —(NR4)2, hydroxyalkyl, alkoxy, —SO2C1-C3alkyl, arC1-C3alkyl, heteroalkyl, C2-C4 alkynyl, —X-haloalkyl, —X-C1-C5 alkyl, —Z-C1-C5 alkyl, heterocyclyl, —X-L-cycloalkyl, —Z-cycloalkyl, —X-aryl, —Z-aryl, or —X-heteroaryl, wherein the heterocyclyl, the cycloalkyl, the aryl and the heteroaryl are optionally substituted with one or more R5.

### Claim 10 (depends on 6)

The compound according to claim 6, wherein the heteroaryl is pyrazolopyridinyl, optionally substituted with one or more R2.

### Claim 11 (depends on 10)

The compound of claim 10, wherein the pyrazolylpyridinyl is substituted with one R2, wherein the one R2 is alkoxy or —X-aryl.

### Claim 12 (depends on 1)

The compound according to claim 1, wherein R1 is —Y-aryl, wherein Y is —NR4— and the aryl is phenyl optionally substituted with one or more R5.

### Claim 13 (depends on 1)

The compound according to claim 1, wherein R1 is —Y-C1-C5 alkyl, wherein Y is —NR4— and the C1-C5 alkyl is methyl, ethyl or propyl.

### Claim 14 (depends on 1)

The compound according to claim 1, wherein R1 is —Y-arC1-C3alkyl, wherein Y is —NR4— and the arC1-C3alkyl is benzyl.

### Claim 15 (depends on 8)

The compound according to claim 8, wherein the pyridyl is substituted with two R2.

### Claim 16 (depends on 6)

The compound according to claim 6, wherein the heteroaryl is pyrimidinyl, optionally substituted with one or more R2.

### Claim 17 (depends on 16)

The compound according to claim 16, wherein the pyrimidinyl is substituted with one R2.

### Claim 18 (depends on 6)

The compound according to claim 6, wherein the heteroaryl is pyrazolyl, optionally substituted with one, two or three R2 groups.

### Claim 19 (depends on 18)

The compound according to claim 18, wherein the pyrazolyl is substituted with one R2.

### Claim 20 (depends on 19)

The compound according to claim 19, wherein R2 is —X-C1-C5 alkyl, hydroxyalkyl, arC1-C3alkyl, or —X-aryl optionally substituted with one or more R5.

### Claim 21 (depends on 18)

The compound according to claim 18, wherein the pyrazolyl is substituted with two independently selected R2.

### Claim 22 (depends on 21)

The compound according to claim 21, wherein the two R2 groups are (1) independently -t —X-C1-C5 alkyl, (2) —X-C1-C5 alkyl and halogen, (3) —X-C1-C5 alkyl and alkoxy, (4) —X-C1-C5 alkyl and —N(R4)2, —(5) X-C1-C5 alkyl and —X-haloalkyl, (6) —X-C1-C5 alkyl and arC1-C3alkyl, (7) —X-C1-C5 alkyl and —X-L-cyclolalkyl, -(8) —X-C1-C5 alkyl and -heterocyclyl, (9) —X-C1-C5 alkyl and —X-aryl optionally substituted with one or more R5, (10) —X-C1-C5 alkyl and —X-heteroaryl optionally substituted with one or more R5, (11) —X-C1-C5 alkyl and cyanomethyl, (12) —X-C1-C5 alkyl and cyano, (13) cyano and halogen, wherein the halogen is chlorine or fluorine, (14) cyano and —X-L-cycloalkyl, (15) independently halogen, (16) cyano and alkoxy, wherein each X is a bond, (17) cyano and —X-aryl, (18) cyano and —X-heteroaryl, (19) cyano and heterocyclyl (20) halogen and —X-arC1-C3alkyl or X-arC1-C3alkyl substituted with cyano, and (21) halogen and —X-aryl.

### Claim 23 (depends on 6)

The compound according to claim 6, wherein the heteroaryl is imidazolyl, 1H-pyrrolopyridyl, tetrahydropyrazolopyrazinyl, 2H-4λ4-imidazopyrimidinyl, 2H-4λ4-imidazopyridazinyl, or oxazolopyridyl, each substituted with one R2 group, wherein each R2 is —X-C1-C5 alkyl, wherein X is a bond.

### Claim 24 (depends on 6)

The compound according to claim 6, wherein the heteroaryl is imidazopyridyl substituted with one R2 group, wherein R2 is cyano, alkoxy, halogen or —X-C1-C5 alkyl and X is a bond, or the heteroaryl is imidazopyridyl substituted with two R2 groups, wherein one R2 group is halogen and the second R2 group is —X-C1-C5 alkyl, wherein X is a bond, or halogen.

### Claim 25

A compound of Formula (I-D):
or a pharmaceutically acceptable salt thereof:
wherein:
each Y is independently a bond or —NR4—;
each R2 is independently hydroxy, halogen, cyano, cyanomethyl, —(NR4)2, hydroxyalkyl, alkoxy, —SO2C1-C3alkyl, —X-arC1-C3alkyl, heteroalkyl, C2-C4 alkynyl, —X-haloalkyl, —X-C1-C5 alkyl, —Z-C1-C5 alkyl, heterocyclyl, —X-L-cycloalkyl, —Z-cycloalkyl, —X-aryl, —Z-aryl, or —X-heteroaryl, wherein the heterocyclyl, the cycloalkyl, the aryl and the heteroaryl are optionally substituted with one or more R5, or;
each X is independently a bond, O, S, —NR4— or —NR4C(O)—;
each Z is independently a bond, —SO—, —SO2—, —CH(OH)— or —C(O)—;
each L is independently a bond or C1-C3 alkylene;
each R4 is independently hydrogen or C1-C3 alkyl;
each R5 is independently cyano, oxo, halogen, C1-C3 alkyl, hydroxyalkyl, alkoxy, —X-haloalkyl, —Z-cycloalkyl, —X-arC1-C3alkyl, X-arC1-C3alkyl substituted with cyano, —X-L-cycloalkyl, —X-L-heteroaryl optionally substituted with one or more C1-C3alkyl or oxo, or —X-aryl; and
R6 is hydrogen, halogen, C1-C3 alkyl, haloalkyl or alkoxy.

### Claim 26 (depends on 1)

The compound of claim 1, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 1)

The compound of claim 1, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 1)

A pharmaceutical composition, comprising a therapeutically effective amount of a compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

### Claim 29 (depends on 1)

A method for inhibiting PRMT5 activity in a cell, comprising contacting the cell in which inhibition of PRMT5 activity is desired with an effective amount of a compound of Formula (I) according to claim or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising a compound according to claim 1.

### Claim 30 (depends on 1)

A method for treating cancer comprising administering to a patient having cancer a therapeutically effective amount of a compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable salt or solvate thereof, alone or combined with a pharmaceutically acceptable carrier, excipient or diluents.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the cancer is selected from the group consisting of Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Biliary tract: gall bladder carcinoma, ampullary carcinoma, cholangiocarcinoma; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial wcarcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma); Hematologic: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma); Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and Adrenal glands: neuroblastoma.

### Claim 32 (depends on 30)

The method according to claim 30, wherein the cancer is a MTAP-associated cancer.

### Claim 33 (depends on 30)

The method of claim 30, wherein the cancer is hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer, or head and neck cancer.
